

Dr. K S SACHDEVA

Dy. Director General
Head, Central TB Division
Project Director, NTEP



Tel. : 011-2306 3226
011-2306 2980
E-mail : ddgtb@rntcp.org

भारत सरकार
Government of India


स्वास्थ्य एवं परिवार कल्याण मंत्रालय
Ministry of Health & Family Welfare
निर्माण भवन, नई दिल्ली-110108
Nirman Bhavan, New Delhi-110108

D. O. No z-28015/27/2012-TB (Part II)
date: 06/01/2020

Dear STOs/DTOs

As per the recommendations of the Technical Expert Group on Treatment of TB, following changes are to be incorporated in the eligibility criteria, follow up schedule and long term follow up for patients initiated on shorter MDR TB regimen with immediate effect. Patients initiated prior to introduction this modification will continue as per existing regimen

- All RR TB patients should be offered FL LPA in addition to SL LPA at base line and during the course of treatment to detect presence of InhA mutation.
- Exclusion criteria applicable for shorter MDR TB regimen is to updated as
 1. **Non-DST based exclusion criteria:** Pregnancy; any extra-pulmonary disease in PLHIV; disseminated, meningeal or central nervous system TB; intolerance to any drug in the shorter MDR TB regimen or risk of toxicity from a drug in the shorter regimen (e.g. drug-drug interactions)
 2. If result for DST (FQ, SLI, Inh A mutation, Cfx* & Z*) is not available at the time of treatment initiation, the patient who has history of use for > 1 month to Mfx(h), Km, Eto or Cfx are not eligible for shorter MDR TB regimen
 3. **DST based exclusion criteria:** If DST/DRT result for FQ or SLI is resistant or presence of InhA mutation (for Eto)
- Shorter MDR TB regimen should be used as a package and neither replacement of drug (except the use of Am instead of Km) nor extension of treatment duration (beyond 11 months) is permitted. If any modification in composition of regimen is warranted, patient should be switched to appropriate longer regimen.
- Follow up using culture should be carried out at 3rd month, 6th month and at the end of treatment. Follow up using smear microscopy should be carried out, monthly from 3rd month onwards till end of IP, Monthly in extended IP only if previous month S+ve. Any follow up culture positive or smear positive at end of IP/extended IP or end of treatment, DST to be offered by FL & SL LPA and LC DST (Mfx 1.0, Lzd*, Cfx* & Z*) *whenever available, to detect amplification of resistance.
- All patients successfully treated with shorter MDR TB regimen should be screened for presence of TB symptoms at 6th, 12th, 18th and 24th month post treatment. If found symptomatic, evaluate as per the integrated diagnostic algorithm for DR TB.


(Dr. K. S. Sachdeva)

To,
STO (All States & UTs)
DTO (All districts)

Copy of information to:

1. PPS to Jt. Secretary (Public Health), MOHFW, GOI
2. All NRLs, IRLs and C-DST labs